Saluda Medical Expands Access to First and Only FDA-Approved Closed-Loop Surgical Paddle Lead with Full US Commercial Release of CAP24â¢PR NewswireBLOOMINGTON,
Steelcase faces a complex outlook defined by project-based revenue volatility and persistent margin pressure, as evidenced by operating margins that swung from 1.0% to 10.5% over the last ten quarters.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2025Latest Dec 17, 2025 | $0.30+15.4% vs $0.26 | — vs — |
Q4 2025 Sep 24, 2025 | $0.45+21.6% vs $0.37 | $897M+2.7% vs $874M |
Q3 2025 Jun 25, 2025 | $0.20+66.7% vs $0.12 | $779M+2.2% vs $762M |
Q2 2025 Mar 26, 2025 | $0.26+30.0% vs $0.20 | $788M+0.8% vs $782M |
Saluda Medical Expands Access to First and Only FDA-Approved Closed-Loop Surgical Paddle Lead with Full US Commercial Release of CAP24â¢PR NewswireBLOOMINGTON,
HNI is rated Buy, driven by cyclical Workplace recovery, Steelcase integration, and attractive valuation. Workplace order growth, backlog strength, and macro tailwinds signal accelerating revenue and multi-year earnings growth potential. Steelcase acquisition offers significant cost synergy upside, with cross-selling and margin expansion opportunities not fully reflected in forecasts.
Benchmark SCS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Steelcase Inc. (SCS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $16.14 | $1.85B | 15.82 | 0.2% | 3.81% | 13.13% | 2.56% | |
| $47.26 | $3.43B | 42.58 | 12.37% | 1% | 2.91% | 2.73% | |
| $21.49 | $1.47B | 16.28 | 4.68% | 2.57% | 7.01% | — | |
| $5.81 | $107.99M | -5.23 | -1.87% | -2.91% | -6.58% | — | |
| $6.20 | $97.52M | 38.75 | -25.01% | -1.31% | -2.32% | 1.61% | |
| $71.47 | $382.76M | 11.77 | 4.1% | 6.75% | 19.83% | 1.12% |
Steelcase Inc. (SCS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Steelcase Inc. (SCS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Dec 11, 2025·SEC
Dec 5, 2025·SEC
Nov 25, 2025·SEC
Apr 18, 2025·SEC
Get notified when SCS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Steelcase Inc. (SCS) stock FAQ — growth, dividends, profitability & financials explained
Steelcase Inc. (SCS) reported $3.26B in revenue over the trailing twelve months. Revenue was $3.17B in fiscal year 2025. That is 31% more than the $2.41B of fiscal year 1997.
Steelcase Inc. (SCS) grew revenue by 0.2% in fiscal year 2025, compared with the prior fiscal year.
Yes. Steelcase Inc. (SCS) earned $95.3M in net income over the trailing twelve months (a 2.9% net margin).
Yes. Steelcase Inc. (SCS) pays a dividend that yields 2.56% at the current price, a moderate yield.
Steelcase Inc. (SCS) had a return on equity (ROE) of 13.1% in fiscal year 2025. That is in line with the market's typical 10-15%.
Steelcase Inc. (SCS) had negative free cash flow of $37.3M over the trailing twelve months.